Feasibility of use and informative value of SNIPER® 10, a multipurpose drug urine test, at the hospital stage in children with acute infectious pathology
Keywords:children, infectious pathology, synthetic marijuana, poisoning, test system SNIPER® 10, clinical case
AbstractIn recent years, there has been a clear upward trend in the use of psychoactive synthetic substances — cannabinoids. The consequences of taking psychoactive substances are very severe and dangerous, as they can cause dysfunction of the internal organs, the nervous system and lead to persistent disintegration of personality. The low price of synthetic drugs, availability and “advertising” of their use attracts the attention of adolescents. Therefore, consumption of synthetic drugs by them is spreading with great speed. As evidenced by the data of our review of the literature, in modern domestic scientific works there is no information regarding the incidence and features of the clinical course of synthetic marijuana poisoning in children in Ukraine. However, the issue of clinical signs and effects of poisoning with synthetic narcotic substances in children receives much more attention in foreign publications. Currently, the most specific clinical symptoms occurring after the use of synthetic cannabinoids are well-known. It is worth noting that the symptoms of children poisoning with synthetic drugs can be various and unpredictable, since the drug that is used is a cocktail of various chemical agents. That is why the lack of knowledge of the clinical course of drug poisoning in children among doctors who were not trained in addiction medicine leads to the erroneous preliminary diagnosis, waist of time for carrying out expedient intensive care, significantly increases the financial costs associated with prescription of expensive laboratory and instrumental studies, and increases the risk of lethal consequences. In this article, we present some experience with the use of the SNIPER® 10 express test in children admitted to an infectious hospital.
Castellanos D. Synthetic cannabinoids 2015: An update for pediatricians in clinical practice / D. Castellanos, L.M. Gralnik // World J. Clin. Pediatr. — 2016. — Vol. 5(1). — P. 16-24 doi: 10.5409/wjcp.v5.i1.16.
Acute intoxication caused by a synthetic cannabinoid in two adolescents / T.S. Heath, Z. Burroughs, A.J. Thompson, F.W. Tecklenburg // J. Pediatr. Pharmacol. Ther. — 2012. — Vol. 17(2). — P. 177-181. doi:10.5863/1551-6776-17.2.177.
Zawilska J.B. Spice/K2 drugs — more than innocent substitutes for marijuana / J.B. Zawilska, J. Wojcieszak // Int. J. Neuropsychopharmacol. — 2014. — Vol. 17. — P. 509-525. doi: 10.1017/S1461145713001247.
Shah R. Synthetic drug intoxication in children: recognition and management in the emergency department / R. Shah, C.R. Baum // Pediatr. Emerg. Med. Pract. — 2018. — Vol. 15(5). — P. 1-20.
Influence of law changes affecting synthetic cannabinoid availability and frequency of hospital presentations: 4-year national survey / P. Glue, J. Courts, A. Gray, T. Patterson // N. Z. Med. J. — 2016. — Vol. 129(1433). — P. 37-40.
Mills B. Synthetic Cannabinoids / B. Mills, A. Yepes, K. Nugent // Am. J. Med. Sci. — 2015. — Vol. 350(1). — P. 59-62. doi: 10.1097/MAJ.0000000000000466.
Cooper Z.D. Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal / Z.D. Cooper // Curr. Psychiatry Rep. — 2016. — Vol. 18(5). — Р. 52.
Novel psychoactive substance use by US adolescents: characteristics associated with use of synthetic cannabinoids and synthetic cathinones / M.E. Patrick, P.M. O’Malley, D.D. Kloska, J.E. Schulenberg, L.D. Johnston, R.A. Miech, J.G. Bachman // Drug Alcohol Rev. — 2016. — Vol. 35(5). — P. 586-590. doi: 10.1111/dar.12372.
Castellanos D. Synthetic cannabinoid use: recognition and management / D. Castellanos, G. Thornton // J. Psychiatr Pract. — 2012. — Vol. 18. — P. 86-93. doi: 10.1097/01.pra.0000413274.09305.9c.
A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment / R.J. Tait, D. Caldicott, D. Mountain, S.L. Hill, S. Lenton // Clin. Toxicol. (Phila). — 2016. — Vol. 54(1). — P. 1-13. doi: 10.3109/15563650.2015.1110590.
Warrick B.J. New Psychoactive Substances in Pediatric Patients / B.J. Warrick, A.P. Tataru, R. Gerona // Pediatr. Clin. North Am. — 2017. — Vol. 64(6). — P. 1223-1241. doi: 10.1016/j.pcl.2017.08.003
How to Cite
Copyright (c) 2019 V.A. Mischenko, M.A. Heorhiiants, V.A. Korsunov, M.B. Pushkar, N.S. Porosha, H.A. Stepnova, D.Yu. Matsak
This work is licensed under a Creative Commons Attribution 4.0 International License.